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Abstract
Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen chronically infecting the lungs of patients with
chronic obstructive pulmonary disease (COPD), pneumonia, cystic fibrosis (CF), and bronchiectasis. Cif (PA2934), a bacterial
toxin secreted in outer membrane vesicles (OMV) by P. aeruginosa, reduces CFTR-mediated chloride secretion by human
airway epithelial cells, a key driving force for mucociliary clearance. The aim of this study was to investigate the mechanism
whereby Cif reduces CFTR-mediated chloride secretion. Cif redirected endocytosed CFTR from recycling endosomes to
lysosomes by stabilizing an inhibitory effect of G3BP1 on the deubiquitinating enzyme (DUB), USP10, thereby reducing
USP10-mediated deubiquitination of CFTR and increasing the degradation of CFTR in lysosomes. This is the first example of
a bacterial toxin that regulates the activity of a host DUB. These data suggest that the ability of P. aeruginosa to chronically
infect the lungs of patients with COPD, pneumonia, CF, and bronchiectasis is due in part to the secretion of OMV containing
Cif, which inhibits CFTR-mediated chloride secretion and thereby reduces the mucociliary clearance of pathogens.
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Introduction
Respiratory infections are the greatest cause of disease
worldwide [1]. A study by the World Health Organization
(WHO) determined that the global disease burden of lung
infections exceeds that of HIV/AIDS, cancer and heart disease
and has since 1990 [1]. P. aeruginosa, an opportunistic human
pathogen is commonly associated with respiratory infections,
particularly nosocomial, ventilator-associated infections and pseu-
domonal pneumonia in immunocompromised patients, including
cystic fibrosis, chronic obstructive pulmonary disease (COPD),
ventilator-associated pneumonia, community-acquired pneumo-
nia, and bronchiectasis patients. We have previously demonstrated
that outer membrane vesicles (OMV) secreted by P. aeruginosa
deliver multiple virulence factors into host human airway epithelial
cells via a mechanism involving OMV fusion with airway cell
plasma membrane lipid rafts and trafficking via an N-WASP
induced actin pathway to deliver OMV cargo directly to the host
cytoplasm [2]. This provides a mechanism for P. aeruginosa to alter
host cell biology without the need for contact with airway
epithelial cells, an important consideration in respiratory diseases
where P. aeruginosa resides primarily in the mucus layer above the
host airway epithelium [2].
Cif, a virulence factor secreted in OMV by clinical isolates of P.
aeruginosa, was first described for its ability to decrease the apical
membrane expression of the cystic fibrosis transmembrane
conductance regulator (CFTR) and to reduce chloride secretion
[3,4,5]. The Cif-induced reduction in the apical membrane
abundance of CFTR in airway epithelial cells is due to an
inhibition of the recycling of endocytic vesicles containing CFTR
back to the plasma membrane and redirection of these vesicles to
the lysosome where CFTR is degraded. The mechanism by which
Cif reduces the recycling of endocytic vesicles containing CFTR is
currently unknown, and thus, characterizing this mechanism was
the goal of the present study.
Many bacteria-derived effectors regulate host pathways, includ-
ing intracellular vesicular trafficking and ubiquitination, which
targets proteins for degradation in the lysosome and proteasome
[6,7]. Pathogens frequently target the ubiquitination/deubiquiti-
nation systems of host cells to suppress the innate immune
response and enhance pathogen colonization [8,9]. For example,
Salmonella produces a DUB, SslE, which reduces the cytotoxicity of
Salmonella in macrophages [6]. Altered ubiquitin signaling involves
the delivery by the pathogen of a DUB into host cells, thereby
reducing the host response to bacterial pathogens.
In a recent study, we demonstrated that USP10, a host cell
DUB, deubiquitinates CFTR in endosomes, thereby reducing the
lysosomal degradation of CFTR, and maintaining cell and plasma
membrane CFTR [10]. However, the effect of Cif on USP10 has
not been examined. Thus, the goal of this study was to test the
hypothesis that Cif inhibits USP10, which increases the amount of
ubiquitinated CFTR that is degraded in lysosomes, thereby
reducing cell and plasma membrane CFTR level. The data in
this report demonstrates that Cif stabilizes an inhibitory effect of
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Ras-GAP SH3 domain binding protein-1 (G3BP1) on USP10,
thereby reducing USP10 mediated deubiquitination of CFTR and
increasing the degradation of CFTR in lysosomes. This is the first
example of a bacterial toxin that regulates a host DUB. We
propose that the ability of P. aeruginosa to chronically infect the
lungs of patients with CF, pneumonia, COPD, and bronchiectasis
is due in part to the secretion of OMV containing Cif, which
inhibits CFTR mediated chloride secretion and thus, reduces the
mucociliary clearance of pathogens.
Results
Cif promotes lysosome-mediated degradation of CFTR
To elucidate the mechanism for the reduction of apical
membrane CFTR, we first examined the time course of the effect
of Cif on the amount of CFTR in the plasma membrane. To this
end, purified P. aeruginosa outer membrane vesicles (OMV)
containing the Cif toxin were applied to the apical face of
polarized human airway epithelial cells. P. aeruginosa OMV were
isolated from an overnight culture and diluted to approximate the
OMV produced by 108 bacteria. A bacterial count of 108 to 1010 is
relevant because this is the bacterial density often detected in CF
patient respiratory secretions [11]. After P. aeruginosa OMV
treatment, CFTR was measured in cell lysates by Western blot
analysis and in the apical plasma membrane by cell surface
biotinylation followed by Western blot analysis. Cif rapidly (30–60
minutes) decreased the apical membrane abundance of CFTR and
subsequently reduced CFTR protein levels in the cell lysate
(Figure 1A). OMV purified from P. aeruginosa clinical isolates and
applied to airway epithelial cells also significantly reduced the
apical membrane and cell lysate abundance of CFTR (Figure 1B).
By contrast, OMV isolated from P. aeruginosa lacking Cif had no
effect on CFTR [2].
CFTR has a long half-life at the apical plasma membrane (8–
24 hours) because it is efficiently recycled back to the plasma
membrane after it is removed by endocytosis [12,13,14,15]. Thus,
the ability of Cif to rapidly (30–60 minutes) reduce CFTR
abundance in human airway epithelial cells suggests that Cif
enhances the endocytic removal of CFTR from the apical plasma
membrane and/or reduces the recycling of endocytic vesicles
containing CFTR back to the plasma membrane. In a previous
publication, we demonstrated that Cif did not alter the endocytic
rate of CFTR, but dramatically reduced the recycling of endocytic
vesicles containing CFTR back to the plasma membrane [3]. In
addition, our previous publication also demonstrated that Cif did
not alter the abundance of other apical membrane proteins, like
the transferrin receptor or the GPI-anchored protein, gp114 [3].
To begin to elucidate the mechanism whereby Cif altered
CFTR trafficking, endosomes were isolated by density gradient
purification from polarized human airway epithelial cells that had
been treated with either OMV containing Cif or OMV from the
cif mutant (control, in which the cif gene had been deleted). These
experiments revealed that in control cells, CFTR co-immunopre-
cipitated with Rab5a and Rab11a, a finding consistent with
previous reports that CFTR is localized primarily in early
endosomal (Rab5a-labelled) and recycling endosomal (Rab11a-
labelled) compartments (Figure 1C, [12,13,14,16,17,18]). Al-
though addition of Cif-containing OMV to polarized human
airway epithelial cells did not change the amount of CFTR in early
endosomes (Rab5a compartment), Cif dramatically shifted the
distribution of CFTR from recycling endosomes (Rab11a-
compartment) to the Rab7a, late endosomal compartment
(Figure 1C). These results support the conclusion that Cif redirects
CFTR from endosomes that recycle to the plasma membrane to a
degradative pathway.
To investigate further the trafficking of CFTR in the presence of
Cif, we followed the movement of CFTR through intracellular
compartments via differential centrifugation and Optiprep gradi-
ent fractionation. In these experiments, apical membrane CFTR
was biotinylated and the portion of CFTR that started at the
apical membrane was tracked as a function of time after exposure
to OMV containing or lacking Cif. In control cells (treated with
OMV lacking Cif), most CFTR was present in the membrane
fraction, but CFTR was also present in the endosomal and a small
portion in the lysosomal fraction (Figure 1D). Addition of Cif-
containing OMV reduced the amount of CFTR in the plasma
membrane and in endosomes, and increased the amount of CFTR
in the lysosomal compartment (Figure 1D). These results are
consistent with the results presented in Figure 1C demonstrating
that Cif reduces apical plasma membrane CFTR by redirecting
CFTR from the recycling endocytic pathway (i.e., Rab 11a) to a
lysosomal degradative pathway (i.e., Rab 7 and lysosomes).
Cif targets CFTR to the lysosome via multi-ubiquitination
To provide additional support for the observation that Cif
redirects CFTR to lysosomes for degradation, Cif-containing
OMV were incubated in combination with control (vehicle) or the
lysosomal inhibitors chloroquine or ammonium chloride. Both
chloroquine and ammonium chloride reduced the Cif-mediated
degradation of CFTR (Figure 2A). By contrast, the proteasomal
inhibitor lactacystin had no effect on the Cif-mediated degradation
of CFTR (Figure 2A). Thus, Cif increased the degradation of
CFTR in the lysosome, a conclusion consistent with the results
presented in Figures 1C and D.
The next series of experiments were conducted to elucidate the
cellular mechanism whereby Cif redirected CFTR to lysosomes for
degradation. First, we tested the hypothesis that Cif increased the
amount of ubiquitinated CFTR, since it is known that ubiquiti-
nated CFTR is degraded in the lysosome [10,19]. Airway cells
were treated with Cif-containing OMV for various time points, in
the presence of a lysosomal inhibitor that prevents ubiquitinated
Author Summary
In this manuscript, we present a detailed mechanistic
study of how a secreted P. aeruginosa virulence factor
disrupts mucociliary clearance in the lung by inactivating a
host cell deubiquitinating enzyme (USP10), thereby
facilitating the degradation of the CFTR secretory chloride
channel, which reduces mucociliary clearance by human
airway epithelial cells. To our knowledge, this is the first
report of a bacterial toxin that alters host innate immune
defense by hijacking host proteins involved in the
ubiquitin proteolytic system. P. aeruginosa is recognized
as the most common bacterial pathogen in ventilator-
associated pneumonia and is commonly isolated from
community-acquired pneumonia patients. While P. aerugi-
nosa can cause devastating acute infections, many studies
have documented that P. aeruginosa can also generate
chronic infections in immunocompromised individuals,
including cystic fibrosis, chronic obstructive pulmonary
disease and bronchiectasis patients. In these patients, the
ineffective host immune response to the bacterial
colonization is thought to play a large role in deteriorating
lung function and ultimately the death of the patient. Our
findings have significant implications to the study of P.
aeruginosa infections in the lung, particularly the ability of
P. aeruginosa to disrupt critical host innate immune
response mechanisms.
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Figure 1. Cif redirects CFTR from recycling endosomes to the lysosomal, degradative pathway. A. Cif-containing OMV applied apically to
polarized human airway epithelial cells resulted in a time-dependent reduction in wt-CFTR in cell lysates and the plasma membrane. Lysate CFTR was
assessed by SDS-PAGE and western blot analysis. Cell surface biotinylation followed by SDS-PAGE and western blot analysis was performed to analyze
the effect of Cif-containing OMV on apical membrane CFTR. Control was cells exposed to OMV lacking Cif, Dcif OMV [2]. Solid black bars, apical
membrane CFTR; striped bars, cell lysate CFTR. Quantitation of results found below representative blots. N = 3, * P,0.05 versus control. 95%
confidence intervals (Apical membrane CFTR: control, 100 to 100; 10 min, 92.97 to 71.87; 30 min, 85.47 to 59.15; 60 min, 52.36 to 32.43; 90 min, 44.54
to 30.98; Cell lysate CFTR: control, 100 to 100; 10 min, 87.08 to 113.8; 30 min, 94.25 to 60.72; 60 min, 74.68 to 61.53; 90 min, 48.49 to 36.08). B. Purified
OMV from P. aeruginosa (PA14), a recently isolated laboratory strain, and clinical isolates (CF and pseudomonal pneumonia) applied to airway
epithelial cells for 90 minutes decreased cell lysate and apical membrane abundance of CFTR. Lysate CFTR was assessed by SDS-PAGE and western
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CFTR from being degraded. CFTR was then immunoprecipitated
and western blot analysis was performed using ubiquitin
antibodies. Figure 2B demonstrates that Cif increased the amount
of ubiquitinated CFTR with a time course that is concomitant
with a decrease in the amount of CFTR (Figure 2C).
Several observations support the view that Cif increased the
multi-ubiquitination of CFTR, rather than mono-ubiquitination
or poly-ubiquitination. First, the ubiquitin antibody FK1, which
only recognizes poly-ubiquitinated CFTR, did not identify
ubiquitinated CFTR in the presence of Cif treatment (Figure
S1). Second, the ubiquitin antibody, FK2, which recognizes mono-
and multi-ubiquitinated proteins, recognized immunoprecipitated
CFTR (Figure 2B). Third, the molecular weight of ubiquitinated
CFTR in the presence of Cif increased by ,40 kDa, an amount
greater than 8 kDa, the molecular weight of a single ubiquitin
moiety. Thus, taken together these results are consistent with the
conclusion that Cif enhances the degradation of CFTR primarily
by increasing the amount of multi-ubiquitinated CFTR, and its
subsequent degradation in the lysosome.
Cif inactivates USP10 in the early endosome
Cif may increase the amount of multi-ubiquitinated CFTR, and
thereby its degradation in lysosomes, by activating an E3 ligase
and/or by inactivating a DUB. To determine the mechanism by
which Cif increases the amount of multi-ubiquitinated CFTR, Cif
was applied to polarized human airway epithelial cells in OMV,
followed by immunoprecipitation of Cif to identify Cif-interacting
proteins. Mass spectrometry of the immunoprecipitated proteins
revealed interaction of Cif with several DUBs, including Ubiquitin
Specific Protease-10 (USP10) and USP34 (data not shown). We
previously reported that the DUB USP10 deubiquitinates CFTR
in early endosomes of human airway epithelial cells [10].
To determine if Cif inhibits the activity of USP10, and thereby
increases the amount of ubiquitinated CFTR, we used a DUB
activity assay to measure USP10 activity in early endosomes (EE)
of airway epithelial cells [10,20,21,22]. The DUB activity assay
employs a HA-UbVME probe that forms an irreversible, covalent
bond only with active DUBs. Identification of DUBs covalently
linked to the HA-UbVME probe was achieved by immunopre-
cipitation of the HA-UbVME-DUB complex using an anti-HA
monoclonal antibody followed by SDS-PAGE and western blot
analysis for the DUB of interest. Using this assay, we demonstrated
that USP10 activity was inhibited 4964% by Cif (Figure 3A). Cif
did not alter the activity of other EE-resident DUBs including
USP8 or USP34, thereby demonstrating the specificity of Cif in
EE for USP10 (Figure 3A). Moreover, silver stain analysis of the
DUB activity assay revealed that Cif does not alter the activity of
any DUBs in addition to USP10 (data not shown).
To provide additional support for the hypothesis that Cif
inactivation of USP10 is responsible for the increase in the amount
of ubiquitinated CFTR and its lysosomal degradation, we
examined the amount of multi-ubiquitinated CFTR following
siRNA knockdown of USP10. siRNA-mediated reduction of
USP10 protein expression (by 7664%, Figure 3C) increased the
amount of ubiquitinated CFTR (Figure 3B, [10]). These data are
consistent with the view that Cif reduces USP10 activity and
thereby increases the amount of multi-ubiquitinated CFTR and its
degradation in the lysosome.
Cif stabilizes USP10 and G3BP1 interaction to inhibit
USP10 activity
The next set of experiments was designed to elucidate how Cif
inhibits USP10 activity. Three observations suggest that Cif may
inhibit USP10 activity by stabilizing the interaction between
USP10 and G3BP1, which inhibits USP10 DUB activity, and also
reduces the interaction between USP10 and CFTR. First,
published studies have shown that USP10 and G3BP1 interact
in yeast and mammalian systems [23,24,25]. Second, in U2OS
bladder cancer cells, the interaction between G3BP1 and USP10
inactivates the deubiquitinating enzyme activity of USP10 [23].
Third, our preliminary mass spectrometry experiments revealed
that Cif and G3BP1 interact (data not shown). Thus, studies were
conducted to determine if Cif inhibits USP10 activity by stabilizing
the interaction between USP10 and G3BP1, and by reducing the
interaction between USP10 and CFTR. As shown in Figure 4A,
USP10 interacts with CFTR in the early endosomes isolated from
airway epithelial cells, and Cif reduces this interaction by 5066%.
Moreover, Cif increased the interaction between G3BP1 and
USP10 by 210612% (Figure 4B). Thus, these observations reveal
that Cif stabilizes an interaction between USP10 and G3BP1, and
also reduces the interaction between USP10 and CFTR.
To provide additional support for the immunoprecipitation
studies demonstrating that Cif increases the interaction between
G3BP1 and USP10 in the early endosomal compartment, we
performed bimolecular fluorescence complementation (BiFC)
studies. BiFC utilizes two half yellow fluorescent protein (YFP)
sequences fused to two hypothetical interacting proteins (USP10
and G3BP1). If two fusion proteins interact (e.g., 1-154YFP-
USP10 (YN-USP10) and 155-238YFP-G3BP1 (YC-G3BP1)), a full
YFP protein is formed and fluorescence is detected via confocal
microscopy [26]. Moreover, by co-transfecting cells with organelle
markers, it is possible to identify the compartment where USP10
and G3BP1 interact. In control experiments transient transfection
of any one of the eight half-YFP constructs alone in airway
epithelial cells did not result in fluorescence in the yellow channel,
blot analysis. Cell surface biotinylation followed by SDS-PAGE and western blot analysis was performed to analyze the effect of clinical isolate OMV on
apical membrane CFTR. N = 3, * P,0.05 versus control. 95% confidence intervals (Apical membrane CFTR: control, 100 to 100; PA14, 40.59 to 16.01; CF
isolate, 36.47 to 15.22; pneumonia isolate 1, 43.51 to 1.545; pneumonia isolate 2, 30.49 to 5.482; Cell lysate CFTR: control, 100 to 100; PA14, 52.80 to
34.47; CF isolate, 50.77 to 28.91; pneumonia isolate 1, 52.89 to 21.02; pneumonia isolate 2, 38.62 to 20.69). C. Cif redirects CFTR from the recycling
pathway to the lysosomal pathway. CFBE cells were incubated with OMV containing Cif, or with OMV lacking Cif (DCif-OMV), for 90 minutes and then
endosomes were isolated as described in Methods. Subsequently, co-immunoprecipitation studies were conducted to determine the subcellular
location of CFTR in control (DCif-OMV) and Cif OMV treated cells (left). Rab5a is a marker of early endosomes, Rab11 is a marker of recycling
endosomes, and Rab7 is a marker of late endosomes. Thus co-immunoprecipitation of CFTR with: Rab5a identifies the amount of CFTR in early
endosomes, Rab11a identifies the amount of CFTR in recycling endosomes, and Rab7 identifies the amount of CFTR in late endosomes. Quantification
of data below for Rab immunoprecipitation with CFTR in the presence and absence of Cif OMV treatment, normalized for the amount of CFTR
immunoprecipitated. N= 3, *P,0.05 versus control. 95% confidence intervals (Rab5a: 112.4 to 87.79; Rab7a: 41.44 to 1.746; Rab11a: 354.6 to 152.5). D.
Optiprep gradient fractionation and differential centrifugation analysis of CFTR after 90 minutes incubation with Cif-containing OMV or control OMV
(DCif-OMV) reveals a redistribution of CFTR from the plasma membrane and endosomes in control cells to lysosomes in Cif-treated cells. Data
presented as CFTR detected in each fraction (by Western blot analysis) as a percentage of the total CFTR detected in all fractions. Plasma membrane,
endosome and lysosomes designated in fractions based on Western blot of fraction for Na+/K+ ATPase, EEA-1 and Rab5a, and LAMP-1, respectively.
Experiment performed 3 times.
doi:10.1371/journal.ppat.1001325.g001
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as expected (Figure 4C and not shown). By contrast, co-
transfection of both constructs (YN-USP10 and YC-G3BP1)
yielded YFP fluorescence (Figure 4C). Combinations of USP10
and G3BP1 constructs with different orientation of the half YFP
protein in the fusion proteins (N- or C-terminus) achieved varying
degrees of BiFC fluorescence (Figure 4C and not shown).
Figure 2. Cif induces the lysosomal-mediated degradation of CFTR in polarized human airway epithelial cells. A. Lysosomal inhibitors
[chloroquine (200 mM) and NH4Cl (50 mM)] block the Cif-mediated degradation of CFTR, as assessed by Western blot analysis for CFTR in cells treated
for 90 minutes with DCif-OMV (Control) or Cif-containing OMV, whereas the proteasomal inhibitor lactacystin (50 mM) had no effect on CFTR
degradation. CHX, cycloheximide. All experiments, except control, were performed in the presence of 5 ng/ml cycloheximide to prevent protein
synthesis, which could mask the effect of Cif OMV on CFTR degradation. Experiments were repeated at least 3 times, * p,0.05 versus control. 95%
confidence intervals (Control, 0.55 to 0.71; CHX, 0.51 to 0.79; OMV, 0.21 to 0.34; CHQ+OMV, 0.49 to 0.69; NH4Cl+OMV, 0.48 to 0.65; Lactacystin+OMV,
0.22 to 0.30). B. Ubiquitinated CFTR was assessed by immunoprecipitation of CFTR and Western blotting for ubiquitin with the FK2 ubiquitin antibody
in cells treated with DCif-OMV or Cif-containing OMV (90 min treatment). Western blotting with the FK1 ubiquitin antibody, that detects
polyubiquitinated proteins, did not show a change in labeling after Cif treatment (data not shown). Ubiquitination experiments were performed in
the presence of 200 mM chloroquine to allow detection of ubiquitinated CFTR, which is degraded too fast to be detected in the absence of a
lysosomal inhibitor. Experiments were repeated at least 3 times, * p,0.05 versus control. 95% confidence intervals (Control, 92.47 to 107.45; 30 min,
98.48 to 138.56; 60 min, 175.25 to 280.34; 90 min, 289.10 to 302.83) C. Cif-containing OMV applied to airway epithelial cells elicited an increase in
multi-ubiquitinated CFTR, concurrent with a reduction in cell lysate CFTR. Cells treated with DCif-OMV (control) or Cif-containing OMV (90 min
treatment) were assessed via western blot analysis for CFTR abundance. Quantitation for Western blot experiments is presented with representative
blots. All experiments were repeated at least 3 times, * p,0.05 versus control. 95% confidence intervals (Control, 98.45 to 103.76; 30 min, 90.47 to
76.29; 60 min, 72.19 to 53.73; 90 min, 43.10 to 31.39).
doi:10.1371/journal.ppat.1001325.g002
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Figure 3. Cif selectively inhibits USP10 activity in early endosomes. A. Cif-containing OMV reduced the activity of a 110 kDa
deubiquitinating enzyme (DUB) as assessed by a DUB activity assay in cells treated with DCif-OMV (Control) or Cif-containing OMV (15 min treatment;
see Methods and [20,21,45]). The DUB activity assay employs a HA-UbVME probe that forms an irreversible, covalent bond only with active DUBs.
Identification of DUBs covalently linked to the HA-UbVME probe was achieved by immunoprecipitation of the HA-UbVME-DUB complex using an
anti-HA monoclonal antibody followed by SDS-PAGE and western blot analysis. The 110 kDa DUB was identified as USP10 by Western blot. USP34
and USP8 were also identified in early endosomes by western blot, however, the DUB activity assay revealed that USP34 was active, but its activity
was not altered by Cif. By contrast, USP8 activity was not detected. Quantitation for all western blot experiments is presented to the right. All
experiments were repeated at least 3 times, * p,0.05. 95% confidence intervals (USP10: control, 100 to 100; OMV, 61.66 to 39.20; USP34: control 100
to 100; OMV, 136.70 to 44.31). B. siRNA knockdown of USP10 abundance recapitulates the Cif-mediated increase in CFTR ubiquitination, as assessed
by immunoprecipitation of CFTR and western blotting for multi-ubiquitinated CFTR in Cif OMV or siRNA-USP10 treated cells. Experiments were
performed in the presence of 200 mM chloroquine to allow accumulation and detection of ubiquitinated CFTR. siNeg, nonspecific, scrambled siRNA
served as negative control for siRNA transfections. IgG, immunoprecipitation using a non-immune IgG was used as a negative control. Black boxes
highlight multi-ubiquitinated CFTR on blots. Quantitation for western blot experiments is presented beside representative blots. All experiments
were repeated at least 3 times, * p,0.05. 95% confidence intervals (siNeg, 0.88 to 1.14; siNeg+OMV, 1.87 to 3.30; siUSP10, 2.35 to 3.61). C. siRNA
knockdown of USP10 reduces USP10 protein levels in airway cells, as assessed by western blot analysis. A USP10 representative western blot is shown
for cell lysates from experiments in Figure 3B, detecting ubiquitinated CFTR.
doi:10.1371/journal.ppat.1001325.g003
Cif Induces Lysosomal Degradation of CFTR
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Figure 4. Cif disrupts CFTR-USP10 interaction by stabilizing the USP10-G3BP1 interaction. A. Cif-containing OMV decrease the
interaction of CFTR with USP10 in the early endosomes of airway epithelial cells, as assessed by immunoprecipitation of USP10 from EE and western
blot analysis for CFTR in cells treated with DCif-OMV or Cif-containing OMV (90 min treatment). Quantitation of USP10-CFTR immunoprecipitation,
normalizing for USP10 immunoprecipitation efficiency, is presented at the bottom of the panel. IgG, immunoprecipitation using a non-immune IgG
was used as a negative control. All experiments were repeated at least 3 times, * P,0.05 versus control. 95% confidence intervals (Control, 100 to 100;
OMV 56.41 to 48.29). B. Cif-containing OMV increase the interaction of G3BP1 with USP10 in the early endosomes of airway epithelial cells, as assessed
Cif Induces Lysosomal Degradation of CFTR
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Experiments in Figures 4d–f were performed with the constructs
yielding maximal BiFC fluorescence intensity under control
conditions, YN-USP10 and YC-G3BP1 (Figure 4C).
To provide additional support for our immunoprecipitation
studies that the interaction between USP10 and G3BP1 occurs in
early endosomes (Figure 4B), BiFC experiments were performed in
cells transduced with a baculovirus system expressing eRFP-
labeled Rab5a (an early endosomal protein) to label early
endosomes. Co-localization of the BiFC signal with the early
endosomal marker was quantified by intensity correlation analysis
using Nikon Elements Software. Mander’s overlap coefficients of
0.8460.06 demonstrated a high degree of co-localization of the
USP10-G3BP1 pair with early endosomes (Figure 4D). Treatment
of co-transfected (YN-USP10 and YC-G3BP1) airway epithelial
cells with Cif-containing OMV resulted in an increase in BiFC
signal, confirming an increased (4.3560.30 fold) interaction
between USP10 and G3BP1 in the presence of Cif (Figure 4E)
compared to cells treated with control (Cif mutant OMV). Co-
localization studies revealed that the BiFC signal (USP10-G3BP1
interaction) was localized to the early endosomal compartment
(Rab5a) in airway epithelial cells treated with Cif-containing
OMV (Figure 4F, Mander’s overlap coefficient of 0.7660.11).
These studies support the conclusion that Cif stabilizes the
interaction between USP10 and G3BP1 in the early endosomes.
Finally, if Cif stabilizes an inhibitory interaction between
G3BP1 and USP10, silencing G3BP1 should reduce the Cif-
induced decrease in USP10 activity as well as the Cif-induced
increase in ubiquitinated CFTR, and its degradation in lysosomes.
siRNA-mediated knockdown of G3BP1 protein expression (by
50%63%) eliminated the ability of Cif to inhibit USP10 activity
(Figure 5A). If G3BP1 knockdown prevented the Cif-mediated
inhibition of USP10 activity, we would predict that knockdown of
G3BP1 would also eliminate the increase in multi-ubiquitinated
CFTR and degradation of CFTR induced by Cif. Knockdown of
G3BP1 did, in fact, block the Cif-mediated increase in the amount
of multi-ubiquitinated CFTR (Figure 5B) and enhanced lysosomal
degradation of CFTR (Figure 5C). Notably, siRNA-mediated
knockdown of G3BP1 significantly increased the abundance of
CFTR, most likely because endogenous G3BP1 inhibits USP10
(Figure 5C). Two additional siRNA target sequences for G3BP1
also abrogated the Cif-mediated degradation of CFTR (Figure S2).
Taken together, these data confirm our hypothesis that Cif, by
enhancing G3BP1 interaction with USP10, inhibits the ability of
USP10 to interact with, and deubiquitinate CFTR.
Discussion
To our knowledge this is the first report demonstrating that a
bacterial toxin, Cif (PA2934), regulates a host protein (USP10)
involved in ubiquitination and lysosomal degradation of an ion
channel (CFTR), and thereby modulates the ability of airway
epithelial cells to secrete chloride, an important component of the
innate immune response in the lung. The data in this report
demonstrates that Cif alters the intracellular trafficking of CFTR,
redirecting CFTR from endosomes where CFTR recycles to the
plasma membrane to lysosomes where CFTR is degraded. Our
data support the conclusion that Cif stabilizes an inhibitory effect
of G3BP1 on USP10, thereby reducing its ability to deubiquitinate
CFTR and increasing the degradation of CFTR in lysosomes
(Figure 6). These data suggest that the ability of P. aeruginosa to
chronically infect the lungs of patients with COPD, pneumonia,
CF, and bronchiectasis is due in part to the secretion of OMV
containing Cif, which inhibits CFTR-mediated chloride secretion
and thus, diminishes the clearance of respiratory pathogens by the
mucociliary escalator.
Ubiquitin modification of proteins regulates numerous cell
processes, including protein degradation, intracellular protein
trafficking, and cell signaling [27]. Ubiquitination and deubiqui-
tination are dynamic and regulated processes; over 1000 E3
ligases, which attach ubiquitin moieties to substrate proteins, are
encoded by the human genome, whereas ,90 DUBs remove
ubiquitin from substrate proteins [6,7]. Thus, the amount of an
ubiquitinated protein, and thereby the amount of the protein that
is degraded in lysosomes or the proteasome, is regulated by the
balance between the activity of E3 ligases and DUBs. Importantly,
the abundance of a given protein is thought to be regulated by a
small subset of E3 ligases and DUBs [6,7].
At the present time, two E3 ligases (Nedd4-2 and c-Cbl) have
been shown to regulate CFTR trafficking. In pancreatic cells,
Nedd4-2 regulates CFTR abundance [28], but preliminary studies
from our laboratory demonstrate that silencing Nedd4-2 does not
alter the amount of CFTR in human airway epithelial cells
(unpublished data). Recently, we demonstrated that c-Cbl
ubiquitinates CFTR in airway epithelial cells [29]; however,
siRNA studies from our laboratory demonstrated that siRNA
knockdown of c-Cbl did not inhibit the Cif-mediated increase in
CFTR degradation (unpublished data). Thus, it is unlikely that Cif
increases the amount of ubiquitinated CFTR by activating Nedd4-
2 or c-Cbl. However, it cannot be ruled out that Cif may be
activating an unknown E3 ligase to increase the amount of
by immunoprecipitation of USP10 from an early endosomal fraction and western blot analysis for G3BP1. Control cells were treated with DCif-OMV.
Quantitation of USP10-G3BP1 immunoprecipitation, normalizing for USP10 immunoprecipitation efficiency, is presented at the bottom of the panel.
IgG, immunoprecipitation using a non-immune IgG was used as a negative control. All experiments were repeated at least 3 times, * p,0.05 versus
control. 95% confidence intervals (Control, 100 to 100; OMV 164.7 to 260.5). C. Bimolecular fluorescence complementation experiments confirm
G3BP1 and USP10 interaction in airway epithelial cells. Airway epithelial cells were transfected with expression constructs 1-154YFP-USP10 (YN-
USP10) and 155-238YFP-G3BP1 (YC-G3BP1) individually and in combination, as well as YN-USP10 and G3BP1-YC individually and in combination. Six
other combinations of USP10 and G3BP1 constructs with different orientation of the half YFP protein in the fusion proteins (N- or C-terminus)
achieved varying degrees of BiFC fluorescence (data not shown). Experiments in Figures 4d–f were performed with the constructs yielding maximal
BiFC fluorescence intensity under control conditions, YN-USP10 and YC-G3BP1 (Figure 4c). D. Bimolecular fluorescence complementation
experiments confirm G3BP1 and USP10 interaction in the early endosomal compartment of airway epithelial cells. Airway epithelial cells were
transfected with expression constructs YN-USP10 and YC-G3BP1 and subsequently infected with a baculovirus Rab5a-eRFP construct, which is a
marker of early endosomes (red). Infection with the baculovirus expressing the empty vector had no effect on cellular morphology, and fluorescence
in the red channel in cells infected with this baculovirus was similar to background (data not shown). E. Bimolecular fluorescence complementation
experiments demonstrate an increased G3BP1-USP10 interaction in airway epithelial cells treated with Cif-containing OMV. CFBE cells were
transfected with expression constructs YN-USP10 and YC-G3BP1 and treated with Cif-containing or DCif-OMV (Control). Fluorescence intensity is
expressed as fold change from control. F. Bimolecular fluorescence complementation experiments reveal the increased G3BP1 and USP10 interaction
with Cif treatment is localized primarily to the early endosomal compartment of airway epithelial cells. Airway epithelial cells were transfected with
expression constructs YN-USP10 and YC-G3BP1 and subsequently infected with a baculovirus Rab5a-eRFP construct, which is expressed in early
endosomes (red). Maximum intensity projections are presented for all confocal microscopy images. Scale bars are equal to 20 mm. Ten fields were
imaged per experiment and experiments were repeated at least three times.
doi:10.1371/journal.ppat.1001325.g004
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ubiquitinated CFTR. Additional experiments, beyond the scope of
this study, are required to determine if other E3 ligases
ubiquitinate CFTR in airway epithelial cells and to determine if
Cif regulates the activity of these E3 ligases.
Approximately 90 DUBs remove ubiquitin from target proteins
[6,7]. The effect of these ligases and DUBs are known to be highly
specific. For example, in this and a previous study we observed
that neither USP34, nor USP8 deubiquitinate CFTR, and only
Figure 5. siRNA knockdown of G3BP1 eliminates Cif inhibition of USP10. A. siRNA knockdown of G3BP1 prevented the Cif-mediated
inhibition of USP10 deubiquitinating enzyme activity in the EE fraction, as assessed with the DUB activity assay (using the HA-UbVME probe). Control
cells were treated with Dcif-OMV. Quantification of USP10 DUB activity is presented below. Experiments were repeated at least 3 times, * P,0.05
versus control. 95% confidence intervals (siNeg: Control, 100 to 100; OMV, 61.12 to 34.87; siG3BP1: Control, 100 to 100; OMV, 107.8 to 98.69). B. siRNA
G3BP1 prevented the Cif-mediated increase in CFTR multi-ubiquitination, as assessed by immunoprecipitation of CFTR followed by western blotting
for ubiquitin (clone FK2 antibody). Experiments were performed in the presence of 200 mM chloroquine to block the degradation of CFTR to allow
detection of ubiquitinated CFTR. Black boxes highlight multi-ubiquitinated CFTR on blots. IgG, immunoprecipitation using a non-immune IgG was
used as a negative control. Quantification for all western blot experiments is presented at the bottom of the panel. Experiments were repeated at
least 3 times, * P,0.05 versus control. 95% confidence intervals (siNeg: Control, 102.6 to 98.30; OMV, 173.9 to 272.4; siG3BP1, Control, 108.2 to 68.72;
OMV 96.27 to 51.79). C. siRNA G3BP1 prevented the Cif-mediated lysosomal degradation of CFTR, as assessed by western blot analysis. A similar result
was observed for apical membrane expression of CFTR (data not shown). Quantification for all western blot experiments is presented below
representative blots. Experiments were repeated at least 3 times, * P,0.05 versus control. 95% confidence intervals (siNeg: Control, 100 to 100;
15 min, 147.1 to 57.14; 30 min, 89.36 to 80.44; 60 min, 73.27 to 39.17; 90 min, 60.72 to 27.02; siG3BP1: Control, 100 to 100; 15 min, 159.4 to 51.42;
30 min, 60.22 to 232.5; 60 min, 110.8 to 334.9; 90 min, 86.24 to 303.4).
doi:10.1371/journal.ppat.1001325.g005
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USP10 activity was inhibited by Cif [10,30]. Our results suggest a
model whereby in steady-state conditions, USP10 activity is
regulated by dynamic interactions between its target protein,
CFTR and its negative regulator, G3BP1. Upon P. aeruginosa
infection and OMV delivery of Cif into host cells, the interaction
of USP10 with its negative regulator, G3BP1, is stabilized and
USP10 is sequestered from interaction with CFTR. Thus, CFTR
remains multi-ubiquitinated in early endosomes and is targeted for
lysosomal degradation (Figure 6). It is not currently known which
ubiquitin linkages USP10 targets, but in our study it appears to
target the multi-ubiquitinated CFTR. A previous study reported
that G3BP1 interacts directly with the N-terminus of USP10, a
common protein-protein interaction domain in the USP family of
DUBs for regulation of DUB activity [23]. While our mass
spectrometry data revealed an interaction between Cif and
G3BP1, additional studies are needed to determine if the
interaction is direct or indirect, and to elucidate how Cif stabilizes
the inhibitory protein complex between USP10 and G3BP1.
Given the importance of the host ubiquitin degradation system
in regulating basic cell biology, it is not surprising that many
pathogens have evolved to target the ubiquitin pathway to
promote their colonization of the host. Pathogen effects on E3
ligases to modify host cell function are well documented, but only
recently has pathogen manipulation of the deubiquitinating
machinery of the host been investigated [6,7,8,9,31]. Several
bacterial species have been shown to encode deubiquitinating
enzymes, the majority playing a role in dampening the host
inflammatory response [6,32,33,34,35]. To date, one other host
DUB (i.e., in addition to USP10) has been targeted by a bacterial
species. The host-encoded DUB, Cylindromatosis (CYLD), is
regulated indirectly by bacterial pathogens through changes in its
gene expression, but a mechanism for the altered gene expression
has yet to be reported [36,37,38,39]. Infection with Haemophilus
influenzae or Eschericia coli induces CYLD expression, which down-
regulates the NF-kB inflammatory pathway. CYLD -/- mice have
a hypersensitivity to infection with both Haemophilus influenzae and
Eschericia coli [37,38,39]. On the other hand, the CYLD -/- mice
experience acute lung injury and increased lethality in response to
Streptococcus pneumoniae infection [36]. These opposing effects of
CYLD DUB activity in response to different pathogens suggest a
potential complexity in targeting host DUBs for therapeutic
purposes to combat infection.
Figure 6. Model proposing a mechanism whereby Cif inhibits USP10 activity and reduces the apical membrane abundance of CFTR
in polarized, human airway epithelial cells. In the healthy state (i.e., not infected with P. aeruginosa), CFTR constitutively cycles in and out of the
apical plasma membrane via trafficking through the early endosomal and recycling endosomal compartments. The secretion of Cif in OMV by P.
aeruginosa redirects CFTR from the recycling pathway to the lysosomal, degradative pathway via an increase in the amount of multi-ubiquitinated
CFTR. Cif inhibits the DUB activity of USP10 to increase the amount of ubiquitinated CFTR by stabilizing an inhibitory interaction between USP10 and
G3BP1, and by decreasing the interaction between CFTR and USP10. It is still not known whether Cif directly or indirectly interacts with USP10 and
G3BP1. These effects of Cif reduce the deubiquitination of CFTR in the early endosome and increase the lysosomal degradation of CFTR. Reduced
apical membrane abundance of CFTR reduces Cl- secretion [3,4], and is predicted to diminished mucociliary clearance, severely compromising the
immune defenses of the lung [42,43].
doi:10.1371/journal.ppat.1001325.g006
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To enable therapeutic development targeting bacterial effector
proteins, and thereby bacterial infections, a better understanding
of the mechanism of action of the bacterial effectors is required.
The crystal structure of the Cif toxin has recently been solved and
shows homology with the a/b hydrolase family of bacterial
enzymes [40,41]. Cif catalyzes the hydrolysis of epoxide
compounds, with specific activity against epibromohydrin and
cis-stilbene oxide. Interestingly, mutations to the active site of Cif
that reduce epoxide hydrolase activity also reduce the effect of Cif
on CFTR degradation [40]. Current studies are underway to
elucidate the mechanism by which the epoxide hydrolase activity
of Cif promotes the inactivation of USP10, via enhancement of
G3BP1 interaction, leading to the degradation of CFTR.
The data in this manuscript is relevant to clinical infections by
P. aeruginosa since the Cif toxin is expressed by clinical isolates of P.
aeruginosa and in OMV isolated from CF and pseudomonal
pneumonia patients ([4], unpublished data). Accordingly, taken
together with previous studies on Cif, the data in this paper are
consistent with the view that Cif-mediated reductions in CFTR
abundance (,60%) and chloride secretion (,60%) by human
airway epithelial cells [4] would be expected to reduce mucociliary
clearance in the airway, a critical mechanism of the innate
immune response to eliminate P. aeruginosa and other pathogens
from the airway of patients with COPD, ventilator-associated
pneumonia, CF and bronchiectasis [42,43]. In addition to the
clinical relevance of the Cif toxin on host mucociliary clearance
and innate immune defense this study reports data identifying Cif
as the first bacterial toxin that inactivates a host DUB.
Understanding the mechanism by which bacterial toxins alter
host cell biology provides the basis for therapeutic development
to inhibit toxin function and potentially reduce bacterial
pathogenesis.
Methods
Cell culture
The role of Cif in CFTR degradation was studied in human
airway epithelial cells (CFBE41o- cells, homozygous for the DF508
mutation) stably expressing wt-CFTR (hereafter called airway
epithelial cells). The derivation and characterization of these cells
have been described in detail by several laboratories [13,44].
Airway epithelial cells between passages 18 and 27 were grown
and polarized in an air-liquid interface culture at 37uC for 6–9
days, as described [13].
Identification of active DUBs
To identify active DUBs in airway epithelial cells we used a
chemical probe screening approach designed and described in
detail by Dr. Hidde Ploegh [20,21,45] and recently published by
our laboratory [10]. The specificity of the HA-UbVME probe for
active DUBs was confirmed with the addition of N-ethylmaleimide
(10 mM), which inhibits cysteine protease DUBs, during the
labeling reaction [20,21,45].
Isolation of early endosomes
To determine if USP10 is expressed in early endosomes,
differential centrifugation and fractionation techniques were used
to isolate early endosomes from CFBE cells using a protocol
adapted from Butterworth et al. [46]. Briefly, polarized CFBE cells,
grown on 24 mm permeable membrane supports, were scraped
into phosphate-buffered saline, pelleted, and resuspended in
600 ml of HEPES buffer (250 mM sucrose, 10 mM HEPES,
0.5 mM EDTA at pH 7.4 containing protease inhibitors (Roche
Diagnostic Corp., Indianapolis, IN)). The cells were homogenized
with a Dounce homogenizer and passed through a 22-gauge
needle 20 times. Following a low speed spin (3,0006 g), the post-
nuclear supernatant was diluted 1:1 with 62% sucrose in HEPES
buffer and placed at the bottom of a 4.4 ml ultracentrifuge tube
(Sorvall, Ashville, NC). 1.5 ml of 35% sucrose in HEPES buffer
was layered on top followed by 1.5 ml of 25% sucrose in HEPES
buffer and 0.5 ml of HEPES buffer. The gradients were
centrifuged in a TH-660 rotor at 167,0006 g for 75 min at 4uC,
and the interfaces were collected to isolate the early endosomal
fractions. Western blot analysis for various Rab GTPases was used
to confirm purity of the early endosomal fraction [10].
Optiprep gradient fractionation of plasma membrane,
endosome, and lysosome compartments
To assess the trafficking of Cif through the endocytic trafficking
pathway, we used differential centrifugation and an Optiprep
continuous gradient to separate the plasma membrane, endosome,
and lysosome fractions from airway epithelial cells, a protocol
adapted from a previous study [47]. Plasma membrane (Na/K
ATPase), endosome (early endosomal antigen-1, EEA-1), and
lysosome (LAMP-1) resident proteins were used to identify these
compartments in the fractionations to identify the localization of
CFTR.
Ubiquitination assay
To assess the amount of ubiquitinated CFTR in airway
epithelial cells, a protocol was adapted from Urbe et al. [48] and
recently published by our laboratory [10].
Immunoprecipitation
To determine if CFTR interacts with USP10 in the early
endosome (EE), USP10 was immunoprecipitated from EE
fractions isolated from airway epithelial cell lysates by methods
described previously in detail [12].
Biochemical determination of cell surface CFTR
The biochemical determination of plasma membrane CFTR
was performed by domain selective cell surface biotinylation using
EZ-Link Sulfo-NHS-LC-Biotin (Pierce), as described previously in
detail [49].
RNA-mediated interference
USP10 and G3BP1 protein expression was selectively reduced
using siRNA purchased from Qiagen (Valencia, CA), by methods
described previously [12]. In brief, airway epithelial cells were seeded
at 0.16106 on 24 mm Transwell permeable membrane supports
and on day 4, post-seeding, cells were transfected with HiPerfect
transfection reagent according to the manufacturer’s protocol
(Qiagen, Valencia, CA). Sequences for siRNAs are: siUSP10 sense
59 CACAGCUUCUGUUGACUCUTT 39; siG3BP1 #1 sense 59
GGAGGAGUCUGAAGAGATT 39; siG3BP1 #2 sense 59
CCCUGGUUCCAACAGAAUGTT 39; siG3BP1 #3 sense 59
GAAAGAAAUCCACAGGAAATT 39; siNegative scrambled sense
59UUCUCCGAACGUGUCACGU39. Cells were studied on day 8
post-seeding (i.e., 4 days after transfection with siRNA).
Production of fluorescent fusion proteins
The sequences encoding YFP (1–154) (yellow fluorescent
protein-1–154-peptide) and YFP (155–238) were kindly provided
by Dr. Tom K. Kerppola (University of Michigan Medical School,
Ann Arbor, MI, U.S.A.) [50,51] and cloned onto the N- or C-
terminal end of the human USP10 to produce USP10-YN, USP10-
YC, YN-USP10 and YC-USP10. The human G3BP1 was also fused
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to the same YFP sequences to produce G3BP1-YN, G3BP1-YC, YN-
G3BP1 and YC-G3BP1. The constructs were purchased from
OriGene (pCMV6 vectors, Rockville, MD) and verified by DNA
sequencing.
BiFC confocal microscopy
CFBE-WT cells seeded at 0.16106 on collagen-coated, glass-
bottom MatTek dishes, were transfected with 1 mg of a single
USP10 and G3BP1 BiFC construct using the Effectene transfec-
tion reagent, according to manufacturer’s protocol (Qiagen,
Valencia, CA). All combinations of the USP10 and G3BP1 BiFC
fusion proteins were transfected in pilot experiments and the single
combination demonstrating maximum BiFC fluorescence was
used in remaining experiments (YN-USP10 and YC-G3BP1). Two
days post-transfection, cells were infected with a baculovirus
expressing a RFP-Rab5a plasmid (Organelle Lights Endosomes-
RFP, Molecular Probes, Invitrogen), according to the manufac-
turer’s instructions. Samples were incubated in the presence or
absence of Cif-containing OMV for 15 min at 37uC and then
fixed with 4% paraformaldehyde in PBS for imaging. Z-stack
images (0.4 mm sections) of labeled cells were acquired with a
Nikon Sweptfield confocal microscope (Apo TIRF 100x oil
immersion 1.49 NA objective) fitted with a QuantEM:512sc
camera (Photometrics, Tuscon, AZ) and Elements 2.2 software
(Nikon, Inc.). YFP fluorescence emission was measured at 535/
30 nm and the fluorescence of Rab5a-RFP, a red fluorescent
protein, was measured at 610/30 nm. Experiments were repeated
three times, with ten fields imaged for each experiment.
Antibodies and reagents
The antibodies used were: mouse anti-ezrin antibody, mouse
anti-G3BP1, mouse anti-GFP antibody (BD Biosciences, San Jose,
CA); mouse anti-HA antibody (Santa Cruz Biotechnology, Santa
Cruz, CA); mouse anti-Ubiquitin antibodies (clones FK2 and FK1)
(BioMol, Plymouth Meeting, PA); rabbit anti-USP10 antibody,
rabbit anti-USP34, rabbit anti-USP8 (Bethyl Laboratories,
Montgomery, TX); horseradish peroxidase-conjugated goat anti-
mouse and goat anti-rabbit secondary antibodies (Bio-Rad,
Hercules, CA). CFTR antibodies were used as described
previously [10]. All antibodies and reagents were used at the
concentrations recommended by the manufacturers or as
indicated in the figure legends.
Statistical analysis
Statistical analysis of the data was performed using Graphpad
Prism version 4.0a for Macintosh (Graphpad, San Diego, CA).
When appropriate, experimental triplicates were performed and
all replicates were expressed as a percentage of control before the
mean was determined. Means were compared using a t-test or
ANOVA followed by Tukeys test, as appropriate. P,0.05 was
considered significant. Data are expressed as the mean 6 SEM.
To show data distribution, 95% confidence intervals are presented
in the figure legends.
Accession numbers
Cif (PA2934, NP 251624.1); USP10 (NP 005144.2); G3BP1 (NP
005745.1); Rab5a (NP 004153.2); Rab7a (NP 004628.4); Rab11a
(NP 004654.1); CFTR (NP 000483.3)
Supporting Information
Figure S1 Cif does not alter the poly-ubiquitination of CFTR in
polarized human airway epithelial cells. Poly-ubiquitinated CFTR
was assessed by immunoprecipitation of CFTR and Western
blotting for ubiquitin with the FK1 ubiquitin antibody in cells
treated with DCif-OMV (Control) or Cif-containing OMV
(90 min treatment). Western blotting with the FK1 ubiquitin
antibody, that detects polyubiquitinated proteins, did not show a
change in labeling after Cif treatment. Experiments were repeated
at least 3 times.
Found at: doi:10.1371/journal.ppat.1001325.s001 (1.71 MB TIF)
Figure S2 G3BP1 knockdown, using additional target sequenc-
es, blocks the Cif-mediated degradation of CFTR. A. Transfection
of two additional siRNA for G3BP1 reduces target protein
abundance by 64% and 42% for construct #2 and #3,
respectively. G3BP1 protein levels were determined by western
blot analysis and quantification is present below a representative
blot. B. siRNA for G3BP1 prevented the Cif-mediated lysosomal
degradation of CFTR, as assessed by western blot analysis. Airway
cells transfected with scrambled, siNeg control siRNA or siG3BP1
were treated for 60 minutes with DCif-OMV (Control) or Cif-
containing OMV. Quantification for western blot experiments is
presented below representative blots. Experiments were performed
3 times, * p,0.05 versus control.
Found at: doi:10.1371/journal.ppat.1001325.s002 (2.13 MB TIF)
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